Previous 10 | Next 10 |
home / stock / msclf / msclf news
2023-05-31 05:32:00 ET Satellos Bioscience press release ( OTC:MSCLF ): Q1 GAAP EPS of -C$0.04 in-line. Cash and cash equivalents of C$2.98M. For further details see: Satellos Bioscience GAAP EPS of -C$0.04 in-line
- $55 million equity financing closed - Resourced to advance lead drug candidate into clinical trials Toronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutic...
Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public off...
Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity ...
Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce today that it has fi...
Toronto, Ontario--(Newsfile Corp. - April 19, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the pricing and te...
Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (" Satellos " or the " Company "), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preli...
2023-03-31 07:51:12 ET Satellos Bioscience Inc. press release ( OTCQB:MSCLF ): FY GAAP EPS of -C$0.32. Satellos had cash and cash equivalents of C$1.92M as at December 31, 2022. For further details see: Satellos Bioscience GAAP EPS of -C$0.32
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dys...
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. ( TSXV: MSCL ) ( OTCQB: MSCLF ) (" Satellos " or the " Company "), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dys...
News, Short Squeeze, Breakout and More Instantly...
– Investigational New Drug (IND) enabling preclinical and toxicology studies successfully completed – Initiation of a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) ...
–SAT-3247 treatment improved muscle repair and regeneration in canine model of DMD – SAT-3247 treatment also improved muscle force in this canine model of DMD – Satellos remains on track to initiate a Phase 1 clinical trial in Q3 2024 Satellos Bios...
– Frank Gleeson, Satellos CEO, to participate in a panel discussion titled "Research Row: PPMD Moving the Needle" on June 29, 2024 – Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company d...